Regimens for Drug-Resistant Tuberculosis

To the Editor: Conradie et al. (Sept. 1 issue)¹ report impressive results of the ZeNix trial of a bedaquiline-pretomanid-linezolid regimen for drug-resistant tuberculosis, with doses of linezolid that were lower than the 1200-mg dose that has been associated with adverse events. In this trial performed in South Africa, the country of Georgia, Moldova, and Russia, 9 of the 181 participants (5.0%) had bedaquiline resistance (minimum inhibitory concentration, 2 to 4 μg per milliliter) at baseline. Despite reported 99.8% adherence to the trial regimen, 6 of 9 participants (67%) with bedaquiline-resistant tuberculosis at baseline had a favorable outcome, as compared with.